2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 1,701–1,800 of 2,029
Devi, L., Tiwari, P., & Dada, R. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02680-x · Cited by 1
He, Y., Huo, S., Hao, L., Yue, Z., Jiang, Y., Zhu, J., & Zhou, Z. (2026) · Biology · doi:10.3390/biology15100810
“Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia, primarily resulting from insufficient insulin secretion and insulin resistance [1].”
Pang, B., Li, D., Chen, K., Luo, L., Feng, X., & Wu, J. (2026) · Life · doi:10.3390/life16050843
“…below: (1) randomized controlled trials; (2) individuals with a diagnosis of type 2 diabetes, as defined by American Diabetes Association criteria [18], with a mean age ≥ 45 years (i.e., middle-aged and older adults); (3) a structured exercise regimen of any modality delivered as the…”
Miyazawa, M., Takatori, H., Nishitani, M., Komura, T., Kaji, K., Yano, M., Kitamura, K., Nakai, R., Matsukawa, H., Takemura, N., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02448-8
Wang, Y., & Chen, H. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113340 · Cited by 1
Zhen, X. M., Macdonald, A., Woodham, B. L., Ryan, B., Hng, T., Nettel‐Aguirre, A., Azar, E., Hanna, M., Yap, J., Paulose, J., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113342
Predicting Individuals at Risk of Diabetes Using Machine Learning
Salas-Ramos, B. M., García-Calvillo, I. D., Acosta, J. A. N., & Mendoza-Frías, G. I. (2026) · Cureus · doi:10.7759/cureus.109761
Secular trends in HbA1c levels among children and adolescents with type 1 diabetes
Chou, J., Lin, C., Lin, S.-K. K., Lee, Y.-J., Huang, C.-Y., Kao, Y.-E., Yu, J.-C., & Ting, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1786897 · Cited by 1
Li, L., Hu, Q., Li, M. T., Zhao, Y., Zhang, R., Liu, Y., Tong, X., Zhu, H. Y., Zhang, M., Zhao, Q., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1842475
Zhou, Z., Huang, L., Sheng, L., Chen, W., Yang, C. C.-K., Xie, Y., Wang, Y., Chen, B., Ke, Y., & Wu, Z. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1803128
Meng, Q., Zhang, Z., Lv, L., Wang, X., Wang, L., Ji, L., Li, X., Ma, C., & Zhang, M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1828999
“…7.0 millimoles per liter; a glycated hemoglobin (HbA1c) level of 6.5 percent or higher; self-reported diagnosis; or use of glucose-lowering agents) (24), and hypertension (defined by blood pressure ≥ 140/90 mmHg, self-reported diagnosis, or antihypertensive drug use) (25, 26); (5) laboratory…”
InfluentialGuo, D., Du, X., Zhang, T., Liu, R., & Ma, M.-Q. (2026) · Science Progress · doi:10.1177/00368504261456870
Prevention of Gestational Diabetes Mellitus
Bitan, R., Avnon, T., & Yogev, Y. (2026) · Springer eBooks · doi:10.1007/978-3-032-23479-7_11
Ye, Y., Xu, D., Zhang, S., Yu, H., Liu, Y., Yang, J., & Sun, L. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/6712215
Sari, D., Çelik, A. B., Al, M., Helvacı, N., Kural, A., Şenoymak, M. C., ERBATUR, N. H., Tutar, M., Zámocký, M., & Tutar, Y. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00671-6
“Participants were 30–60 years of age and were grouped based on clinical diagnosis, treatment status, and glycemic parameters in accordance with the American Diabetes Association (ADA) 2024 diagnostic criteria [18 ].”
Jiao, Y., & Ma, J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm54062
Sadrinasab, S., Jeddi, S., Azizi, F., & Ghasemi, A. (2026) · Intern J Endocrinol Metab · doi:10.5812/ijem-167774
“This range is consistent with the American Diabetes Association (ADA) criteria for defining normal fasting glucose [70 - 100 mg/dL (33)], values used at Massachusetts General Hospital (34), and values reported from Nordic countries (35) and Japan (36).”
Vergauwen, J., Bos, P., Danhieux, K., van Olmen, J., & Wouters, E. (2026) · BMC Public Health · doi:10.1186/s12889-026-27990-1
“…two pathways: self-reported diagnosis or medication use, including reports from previous SHARE waves (18.6% of the sample), and undiagnosed cases with HbA1c levels ≥ 6.5% (≥ 48 mmol/mol) who have never received a medical diagnosis nor reported diabetes medication use (8.9% of the sample) [40].”
InfluentialFill in the Gaps - Applying Polynomial-based Imputation techniques for Heart Rate Data
Gupta, V., Grensing, F., Cinar, B., van den Boom, L., & Maleshkova, M. (2026) · IEEE Conference on Artificial Intelligence (CAI) · doi:10.1109/cai68641.2026.11536361
“Patients rely on insulin therapy, yet incorrect dosing can lead to hypoglycemia (blood glucose (BG) levels below 70 mg/dL), which can be life-threatening and often asymptomatic, necessitating early detection and intervention [3].”
Medina, Y. N., de León, S. C., Barreiro-Bautista, M., Dávila‐Batista, V., Fabelo, H. A., Pavlovic, S., Delgado, Y. G., Jiménez, J. E., López-López, S., Wägner, A. M., et al. (2026) · Journal of Nutrition and Metabolism · doi:10.1155/jnme/1016106
“Glucose metabolism disorders were classifed according to ADA criteria [27].”
Bisht, A., & Lieder, B. (2026) · ACS Nutrition Science · doi:10.1021/acsnutrsci.6c00002
Kim, Y.-J., & Lee, S.-K. (2026) · Nutrition Research and Practice · doi:10.4162/nrp.2026.20.3.521
Zhong, X., Chen, Z., Cao, T., Fan, C., Fu, W., Jiang, Y., & Wu, Y. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09160-8
Barrington, C., Wallace, D. D., Ruíz, C., Donastorg, Y., Pérez, M., Gómez, H., Beltre, Y. B., Dockery, M., & Kerrigan, D. L. (2026) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/23259582261455718
Baykal, G. R., Keskin, M., Balsak, B. Ö. T., Keskin, Ç., Özdemir, D., Topaloğlu, O., ERSOY, R., & Çakır, B. (2026) · Bariatric Surgical Practice and Patient Care · doi:10.1177/2168023x261455383
Babini, L., Infantino, M., Garrafa, E., Bonetti, G., Carta, M., & BIZZARO, N. (2026) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.26.00328-2
Yuan, J., Xu, H., Mo, Y., Xiao, S., (40767), Y. Z., Xie, Q., 唐雪莲, & Wen, S. (2026) · Nutrición Hospitalaria · doi:10.20960/nh.06722
Zheng, B., Li, C., Fang, Z., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1819674
Cheng, Y. L., Chou‐Huang, T., Lee, C., Chen, H., Cheng, K., Wu, M.-C., Huang, S.-S., Guo, J., & Wu, J. (2026) · International Wound Journal · doi:10.1111/iwj.70949
Yin, X., Sun, X., Gao, F., Wang, X., Chen, P., Yang, X., Guo, N., Wang, G., Xu, J., & Fu, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1850506 · Cited by 1
“T2DM was diagnosed according to the criteria of the American Diabetes Association (ADA) (14), including the presence of typical diabetic symptoms (polydipsia, polyuria, polyphagia, and weight loss) with a random blood glucose level ≥ 11.1 mmol/L, a fasting blood glucose level ≥ 7.0 mmol/L, or a…”
InfluentialPathak, V., & Aeri, B. T. (2026) · Discover Public Health · doi:10.1186/s12982-026-02195-4 · Cited by 1
“Biochemical assessment: The FBG (classified using American Diabetes Association cut-offs [19] (FBS levels of 100–125 mg/dL indicate pre-diabetes, ≥ 126 mg/dL indicate diabetes) and lipid profile (classified using NCEP-ATP III criteria [20], elevated total cholesterol: ≥200 mg/dL, elevated…”
Jabalera, A. M., Yang, J., Zelicha, H., Hsu, W. W. Y., Pajukanta, P., Bui, A., Li, Z., & Hsiai, T. K. (2026) · Research Square · doi:10.21203/rs.3.rs-9794767/v1
Çamili, F. E., Nurdoğan, F., Polat, E. Ş., et al. (2026) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1917062
Jia, B., Jiang, Z., Wen, X., Yang, M., & Wang, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1831010
Anum, F., Li, X., Brown, R. J., et al. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag128
“Diagnosis of diabetes mellitus was based on self-reported history, previous medical records, and laboratory findings, according to American Diabetes Association's criteria [29].”
Wekalao, J., Almawgani, A. H. M., Alhawari, A. R. H., Alammar, M. M., Abdullah, M., & Rajakannu, A. (2026) · Analytical Biochemistry · doi:10.1016/j.ab.2026.116165
Kashuba, M. O., Лотоцька, О. В., Kopach, O., et al. (2026) · Ukrainian Journal of Occupational Health · doi:10.33573/ujoh2026.01.079
Suherman, L. P., Novalina, D., Kartidjo, P., et al. (2026) · Journal of Pharmaceutical And Sciences · doi:10.36490/journal-jps.com.v9i2.1501
“According to clinical standards, the failure to down-titrate baseline insulin in renal insufficiency significantly escalates the risk of severe, prolonged hypoglycemic events due to delayed metabolic clearance of exogenous insulin[9,16].”
InfluentialWehbi, L., & Haddad, S. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/1454695 · Cited by 1
“T2DM diagnosis followed American Diabetes Association (ADA) criteria: fasting blood glucose ( FBG ) ≥ 126 mg/dL, HbA1c ≥ 6.5% , and/or current use of anti-diabetic medications [19].”
InfluentialLiu, C. C.-Y., König, C. S., & Ramachandran, S. (2026) · Endocrines · doi:10.3390/endocrines7020026
Husain, N., Пенчев, П., Queiroz, S., Salha, I., Cavalcante, D. V. S., von Quednow, E., Singh, M., Agrawal, P. K., & Samajdar, S. S. (2026) · Research Square · doi:10.21203/rs.3.rs-9801867/v1
Ruchi, V., Pallavi, G., Renukadevi, S., et al. (2026) · International Journal of Noncommunicable Diseases · doi:10.4103/jncd.jncd_146_25
Amoako, J. K. A., Kottoh, E., Kwabena-Adade, E. N. A. O., Aikins-Ennin, E., Tenkorang, P. O., Nuakoh, P., Tetteh, G. A., Honyenuga, P. J., Boakye, S. A., Bannerman-Williams, E., et al. (2026) · Global Neurological Insights · doi:10.1016/j.gni.2026.100009
Mikkelsen, R., Larsen, J. B., & Smidt, K. (2026) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2891-4643 · Cited by 1
Amaral, S., Suarez‐Zdunek, M. A., Knudsen, A. D., Fuchs, A., Borges, Á. H., Køber, L., Benfield, T., Kofoed, K. F., Brites, C. R., & Nielsen, S. D. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag311
“…[3], dyslipidemia as low-density lipoprotein cholesterol ≥ 3.0 mM (116 mg/dL) and/ or current use of lipid-lowering agents [12], and diabetes mellitus as nonfasting plasma glucose ≥ 11.1 mmol/L ( ≥ 200 mg/dL) and/ or glycated hemoglobin ≥ 48 mmol/L and/or use of antidiabetics [13].”
InfluentialKamaliZonouzi, S., Semnani, F., Mahiny, D., & Arevalo, J. F. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07290-5
Hypertension management: is lower always better?
Shamsulddin, A. B. (2026) · Minerva Medica · doi:10.23736/s0026-4806.26.09891-5
Gao, Z., Zuo, Y.-Q., Yin, Y., Yang, X., Xu, L., Jia, M., & Yang, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1795702
“…< 1.0 mmol/L. Diabetes mellitus (DM) was defined as self-reported physician-diagnosed diabetes, current use of hypoglycemic medication, or FPG ≥ 7.0 mmol/L; impaired fasting glucose was defined as FPG ≥ 5.6 mmol/L but < 7.0 mmol/L, according to the American Diabetes Association 2024 criteria (16).”
InfluentialLiu, H., Wang, R., Cui, L., Wang, L., Liu, J., Du, Y., Dong, S., & Xia, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1828354
Artificial Intelligence in Self-Management of Gestational Diabetes Mellitus: A Systematic Review
Guo, X., Sun, K., Zhang, R., Yang, X., Zhao, J., Hongxia, C., & He, F. (2026) · Journal of Medical Systems · doi:10.1007/s10916-026-02419-9
Yılmaz, A., Yılmaz, H., KORKMAZ, N. Ç., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124566
Practical Considerations for the Use of Oral Glucagon-like Peptide-1 Receptor Agonist in India
Ashraf, H., Bakshi, S., Ekatpure, H., Kumar, N. S. P., Acharyya, M., Reddy, J. N., Ghosh, J., Goel, A., Chaudhary, R., Saini, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_25_26
Lin, Z., Shi, S., Song, Y., He, J., Yuan, S., & Dou, K. (2026) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.70700
“Diabetes was identified if the patient had a previous diagnosis of diabetes, was receiving treatment to reduce glucose levels, or exhibited fasting blood glucose levels of ≥ 7.0 mmol/L, HbA1c values of ≥ 6.5%, or 2‐h plasma glucose levels of ≥ 11.1 mmol/L during an oral glucose tolerance test [11].”
InfluentialCurrent trends in semaglutide therapy and strategies to improve its bioavailability
Nayak, S., Dessai, A. D., & Nayak, U. Y. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2688990 · Cited by 3
Khobrani, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1827330
Abdu, F. A., Mohammed, A., Zhang, W., Alifu, J., Liu, L., Yin, G., Liao, Y., Zhu, G., & Che, W. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03244-7
“Participants were categorized into three mutually exclusive glycemic groups based on the 2024 American Diabetes Association (ADA) criteria [37].”
Li, T., Zhang, B., Huang, Q., Xu, R., Gao, H., Shi, L., Wang, H. J., Zhao, L., Tang, H., Wang, Y., et al. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-004416
Bulbul, N., Çiftçi, R., Atık, İ., Eken, Ö., Ertürk, N. E., & Aldhahi, M. I. (2026) · Healthcare · doi:10.3390/healthcare14121710
“HbA1c is a well established biomarker in the diagnosis of diabetes [26].”
Kamanlı, B., & KIZILKAYA, H. (2026) · Bozok Tıp Dergisi · doi:10.16919/bozoktip.1847664
Bardenheier, B. H., Rodríguez, B., Mahajan, P., Zaganjor, I., HORA, I. A., & Bullard, K. M. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-004311
“25 Early screening for both diabetes and mental health conditions can lead to more effective treat-ment plans, potentially reducing the burden of diabetes complications and mental health disorders, reducing long-term healthcare costs and improving quality of life.”
Cardio–kidney–metabolic syndrome: Underutilized screening and management in primary care settings
Zayan, T. A., & Khafagy, H. A. (2026) · World Advances in Renal Medicine · doi:10.25259/warm_24_2025
Li, C., Jiang, C., Li, N., Sun, L., Cheng, Y., liu, L., Wang, Y., Zou, Y., Wu, Z., & Tang, Y. (2026) · Chinese Journal of Academic Radiology · doi:10.1007/s42058-026-00228-0
“…were selected based on the following criteria: (1) The T2DM group was diagnosed according to the American Diabetes Association (ADA) guidelines [ 15]; the control group was composed of non-T2DM subjects who visited or underwent health examinations at the same institution during the same period;…”
Glucose-lowering agents and hepatocellular carcinoma
Lai, S., & Liao, K. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04107-6
“To date, no professional guideline recommends initiating or switching glucose-lowering agents for the purpose of reducing HCC incidence, and HCC prevention is not recognized as a clinical endpoint in diabetes care.”
Usmagambetov, D. (2026) · West Kazakhstan Public Health Journal · doi:10.4103/wkpj.wkpj_23_26
Naz, S., Yazdani, N. S., Hoodbhoy, Z. A., Ghebremichael‐Weldeselassie, Y., Mazhar, A., Hotwani, A., Jehan, F., Nisar, M. I., & Iqbal, R. (2026) · BMJ Open · doi:10.64898/2026.06.08.26355138
Fenugreek-associated hypoglycemic coma: potentiation of insulin therapy in diabetic patients
Skalli, S. (2026) · Drugs & Therapy Perspectives · doi:10.1007/s40267-026-01259-4
Mendoza, K., Marrero, A., Taméz, M., Espinosa, A., Sotres‐Alvarez, D., McClain, A. C., Cordero, C., Elfassy, T., Perreira, K. M., Mossavar‐Rahmani, Y., et al. (2026) · American Journal of Epidemiology · doi:10.1093/aje/kwag139 · Cited by 1
Li, J., Shen, X., Zhang, J., Cheng, X., Zhang, X., Wang, Y., & Yang, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1861404
Hasnat, M. A., Khanam, M. H., Fatima, S. U. K., Hasan, Z., Mia, M. W., Khan, J., & Talukder, M. M. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02343-6
“Its incidence is noticeably increasing globally, posing significant short-and long-term health risks to both the mother and the fetus [9, 10], including the development of type 2 diabetes mellitus (T2DM), metabolic disorders, and kidney and cardiovascular diseases even later in life [11, 12].”
Liu, Q., Zheng, K., & Hou, L. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02370-3
“…random blood glucose level ≥ 200 mg/dL (11.1 mmol/L), HbA1c level ≥ 6.5%, currently using diabetes medication, or self-reported diagnosis of “Have you ever been diagnosed by a doctor with diabetes or high blood sugar?” based on standards published by the American Diabetes Association by 2024 [33].”
InfluentialLiu, M., Peng, P., Chen, J., et al. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05099-2
“Diabetes mellitus (DM) was diagnosed according to the 2024 American Diabetes Association (ADA) criteria [36].”
Fu, G., Ling, J., Ling, D., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1756050
Sezer, B. B., Limnili, G., & Özçakar, N. (2026) · Complementary Medicine Research · doi:10.1159/000553036
Trần, T. T. T., Thanh, K. M., Tran, N. H., et al. (2026) · Physiology International · doi:10.1556/2060.2026.00804
Selvi, R. S., Mubarakali, A., Elshafie, H., et al. (2026) · IEEE Transactions on Plasma Science · doi:10.1109/tps.2026.3703351
“Therefore, the availability of these devices is limited in resource-poor countries [5].”
Management of Geriatric Diabetic Neuropathy
Helvacı, G., & Ustaömer, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00158-3
Zhao, W., Tang, R., Tian, J., & Gao, D. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03230-z
“Prehypertension was defined as SBP between 120 and 140 mmHg and/or DBP between 80 and 90 mmHg [31].”
Tea Intake and Sleep Parameters in Patients with Type 2 Diabetes Mellitus
Batra, A., Mangla, P., Kumar, A., Jain, M., Jain, A., Raizada, N., & Madhu, S. V. (2026) · doi:10.5005/ujms-11060-0009
Fatima, F., Fawwad, A., Basit, A., Abbas, E., & Aftab, R. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02383-y
Type 2 diabetes mellitus + glaucoma = type 4 diabetes mellitus
Sotak, Š. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.053
Xie, C., Xie, C., & Chen, C. (2026) · Critical Public Health · doi:10.1080/09581596.2026.2690727
Moshawih, S., Gharaibeh, L., Alfreahat, I., & Shnoudeh, A. J. (2026) · Medical Sciences · doi:10.3390/medsci14030343 · Cited by 1
“These trends reflect the higher therapeutic burden among individuals with CVD. Hypertension, hyperlipidemia, and diabetes prevalence were determined in accordance with the American Heart Association (AHA, 2017) [21] and American Diabetes Association (ADA, 2023) [22] guidelines.”
Trevisan, M. E., Gonzatti, N., da Silva, C. C. F., Tonetto, L. D. S., Guex, C. G., Puntel, G. O., SILVA, A. S. D., Signori, L. U., Melazzo, C., Lago, P. D., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02723-3
“Type 2 diabetes (T2D) is a progressive metabolic disorder characterized by chronic hyperglycemia resulting from the combined effects of insulin resistance and β-cell dys - function, leading to multisystem metabolic impairment [1, 2].”
Ntikoudi, A., Evangelou, E., Galanis, P., Owens, D. A., Ventouri, S., Rizikou, D., Papachristou, A., Mastorakos, G. P., & Vlachou, E. D. (2026) · Livers · doi:10.3390/livers6040057
“Glucose tolerance was interpreted according to the American Diabetes Association criteria, whereby normal glucose tolerance was defined as a 2 h plasma glucose level 140 mg/dL, impaired glucose tolerance as 140–199 mg/dL, and diabetes mellitus as ≥ 200 mg/dL [16].”
Peng, Y., Zhang, Y., Jia, C., et al. (2026) · Science Progress · doi:10.1177/00368504261463057
“25,26 Research by Han D et al. 18 have shown that the napkin-ring sign is a significant predictor of NSTE-ACS occurrence.”
The impact of glycemic status transitions on atherosclerotic cardiovascular disease
Fan, B., Dong, Z., Lang, T., & Meng, L. (2026) · TransMed · doi:10.1016/j.tmed.2026.100035
Almallah, A., Abuelsamen, T. R., AlSamhori, J. F., et al. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01696-x
Maddaloni, E., Pezzica, S., Amendolara, R., Sabatini, S., Mocciaro, G., Sebastiani, G., D’Onofrio, L., Carli, F., Tesi, M., Suleiman, M., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06777-4
“These patients are classified as having a less severe form of autoimmune diabetes, named latent autoimmune diabetes in adults (LADA) [5, 6].”
Ghosh, A., Rastogi, A., Sahana, P. K., Agrawal, A. C., Mishra, A. K., Mohanty, D., Bodhey, N. K., Agarwala, P., Nanda, R., Bhattacharyya, M., et al. (2026) · JMIR Research Protocols · doi:10.2196/93492 · Cited by 1
“Diagnosis of diabetes mellitus will be as per the American Diabetes Association Standards of Care in Diabetes 2024 [26].”
Risk factors for sepsis: a systematic review and meta-analysis
Qin, C., Lin, S., Pang, L., Hu, M., Ma, D., Zhou, Z., Xu, X., & Ji, C. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1790141 · Cited by 1
“At the community level, health education should be enhanced in accordance with the Standards of Medical Care in Diabetes (56), promoting nutritional therapies such as healthy dietary patterns (e.g., the Mediterranean diet) and the development of individualized meal plans, along with encouraging regular physical activi…”
Xiang, F., Li, M., Li, R., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113399
Park, J. Y., Lee, J., Kang, S. M., Kim, Y. W., Han, B., Kim, D. H., & Yoon, J. (2026) · BMC Public Health · doi:10.1186/s12889-026-28152-z
“T2DM was defined based on the following criteria: (1) an FBG of ≥ 126 mg/dL, or (2) ICD-10 codes E11 to E14 with the current treatment involving anti-diabetic medications [16].”
InfluentialKaminer, J., Kartsonaki, C., Sherliker, P., Yang, L., Iona, A., Pei, P., Chen, Y., Sun, D., Yang, X., Lu, Y., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-109377
Qin, Z., Qin, S., Li, X., & Liang, B. (2026) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2026.108692 · Cited by 1
Liang, Q., Xiong, Y., Huo, Z., Li, S., Wan, S., Zeng, T., Liu, W., Wang, F., Luo, C., Xu, F., et al. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120417
Hu, Y., 徐雪梅, Chen, J., Xu, J., Tang, L., Wang, K., & Wang, X. (2026) · Research Square · doi:10.21203/rs.3.rs-9734820/v1
Nazirkulov, O., Abdullayeva, N., Ziyadullaev, S., et al. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02515-4
Wu, L., Chang, D., Zhao, M.-H., Tang, S. C. W., & Chen, M. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05162-y
“DM was identified as at least one of these: fasting plasma glucose ≥ 7.0 mmol/L, HbA1c ≥ 6.5%, or the administration of glucose-lowering drugs [21].”
InfluentialEspeche, W. G., Cerri, G., Minetto, J., Sisnieguez, C. E. L., Calvo, S. P., Giordani, E., Costa, M., Gómez, D. R., Iraola, A. D., & Salazar, M. R. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01988-3
“T2D was defined as self-reported diabetes in the NHIS question - naire together with either pharmacological treatment or ful - fillment of the diagnostic criteria proposed by the American Diabetes Association (ADA) [9].”
Gao, Q., Jiang, N., Liu, X., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1872715
“The inclusion criteria were as follows: (1) diagnosis of T2DM according to the American Diabetes Association (ADA) criteria (16); (2) postmenopausal women or men aged ≥ 50 years; (3) availability of complete clinical data, including neutrophil percentage, serum albumin, and BMD measurements.”
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.